Leigh Ellis - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock Leigh Ellis's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
Leigh Ellis

Leigh Ellis

Verified

NBA Analyst, No Dunks (Podcast)

Atlanta

Final Covers

snowboardSki

Journalist Type

-

Seniority Positions

-

Industries

-

Medium Formats

Content

Total articles 12

  • Genetic and biological drivers of prostate cancer disparities in Black men - Nature Reviews Urology

    By Jun Gong, Michael Freeman, Leigh Ellis, Dan Theodorescu| Nature Verified AbstractBlack men with prostate cancer have historically had worse outcomes than white men with prostate cancer. The causes of this disparity in outcomes are multi-factorial, but a potential basis is that prostate cancers in Black men are biologically distinct from prostate cancers in white men.

    By Jun Gong, Michael Freeman, Leigh Ellis, Dan Theodorescu · Nature

    Nov. 14, 2023

  • MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer

    By Leigh Ellis, Jagpreet Singh, Deborah L. Burkhart, Beatriz German| bioRxiv@ AbstractPhenotypic plasticity is a recognized mechanism driving therapeutic resistance in prostate cancer (PCa) patients. While underlying molecular causations driving phenotypic plasticity have been identified, therapeutic success is yet to be achieved.

    By Leigh Ellis, Jagpreet Singh, Deborah L. Burkhart, Beatriz German · bioRxiv

    Feb. 02, 2024

  • MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer

    By Leigh Ellis, Jagpreet Singh, Deborah L. Burkhart, Beatriz German| bioRxiv@ AbstractPhenotypic plasticity is a recognized mechanism driving therapeutic resistance in prostate cancer (PCa) patients. While underlying molecular causations driving phenotypic plasticity have been identified, therapeutic success is yet to be achieved.

    By Leigh Ellis, Jagpreet Singh, Deborah L. Burkhart, Beatriz German · bioRxiv

    Feb. 02, 2024

As seen in

Company Info

No Dunks (Podcast)

Atlanta, United States